|
Jul 1
|
Bausch + Lomb Combines Patient Voices and New Survey Insights to Combat Persistent Misconceptions about Dry Eye
|
|
Jun 30
|
Insider Stock Buying Reaches US$1.54m On Bausch + Lomb
|
|
Jun 30
|
Bausch + Lomb Will Release Second-Quarter 2025 Financial Results on July 30 and Hold Investor Day on Nov. 13
|
|
Jun 26
|
Bausch + Lomb Closes Senior Secured Notes Offering, Refinancing And Upsizes US$2.32 Billion Term Loan Facility
|
|
Jun 26
|
Bausch + Lomb Announces Closing of Upsized €675 Million Senior Secured Notes Offering and Partial Credit Agreement Refinancing, Including Upsized $2.325 Billion Term Loan Facility
|
|
Jun 25
|
The Top 5 Analyst Questions From Bausch + Lomb’s Q1 Earnings Call
|
|
Jun 18
|
Bausch + Lomb Prices Upsizes and Prices a 675-Million Euro Senior Secured Notes Offering
|
|
Jun 18
|
Bausch + Lomb Announces Pricing of Upsized Senior Secured Notes Offering
|
|
Jun 10
|
Bausch + Lomb Announces Launch of Senior Secured Notes Offering and Refinancing of Credit Agreement
|
|
May 7
|
Bausch + Lomb Receives European CE Mark Approval for Preloaded LuxLife® Full Range of Vision Intraocular Lens
|
|
Feb 14
|
Stocks to watch this week: Alibaba, Walmart, HSBC, Rio Tinto and Lloyds
|
|
Jan 3
|
Bausch + Lomb price target lowered to $22 from $25 at Evercore ISI
|
|
Jan 2
|
Bausch + Lomb to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
|
|
Oct 9
|
Bausch + Lomb Will Release Third-Quarter 2024 Financial Results on October 30
|
|
Jun 17
|
Bausch + Lomb Announces Presentation of New Data at the European Dry Eye Society 2024 Congress
|
|
Nov 28
|
Bausch + Lomb CEO Brent Saunders Pays $35.35 Million for Cher’s Former Miami Beach Home
|
|
Sep 20
|
Bausch + Lomb’s ONE by ONE and Biotrue® Eye Care Recycling Programs Recognized As Sustainability Service of the Year Award Winners
|
|
Sep 19
|
Is the Options Market Predicting a Spike in Bausch + Lomb (BLCO) Stock?
|
|
Sep 18
|
Novartis' (NVS) Shareholders Approve Sandoz Separation
|
|
Sep 6
|
Bausch + Lomb Announces Disclosure of Historical and Pro Forma Financial Information With Respect to Acquisition of XIIDRA®
|